China’s National Medical Products Administration granted approval to Innovent Biologics for Tabosun (ipilimumab N01, IBI‑310) in combination with sintilimab as a neoadjuvant treatment for stage IIB–III resectable MSI‑high/dMMR colon cancer. The decision makes Tabosun the first domestically developed CTLA‑4 monoclonal antibody approved in China for this indication. Innovent will position the regimen for preoperative use in high‑risk, resectable disease, leveraging clinical data submitted to the NMPA. The approval highlights China’s regulatory flexibility for oncology combinations and will intensify competition in checkpoint inhibitor pairings within the Chinese colorectal cancer market.